Thomas Fischer

Projects

• Targeting the innate immune system for Multiple Sclerosis / Team member / ongoing
• Inhibitors targeting SARS-CoV-2 proteases / Team member / completed
• Development of new therapeutic approaches for the treatment of cancer / Team member / completed
• Dynamic combinatorial chemistry in drug discovery / Team member / completed

Publications

Articles in scientific journal, peer-reviewed

• Fischer, T., Frasson, D., Sievers, M., & Riedl, R. (2024). Phthalimide derivatives as a new class of papain-like protease inhibitors in SARS-CoV-2. Archiv Der Pharmazie, 358(1), e2400714. https://doi.org/10.1002/ardp.202400714
• Fischer, T., Frasson, D., Sievers, M., & Riedl, R. (2024). Phthalimide derivatives as a new class of papain‐like protease inhibitors in SARS‐CoV‐2. Archiv Der Pharmazie, 358(1), e2400714. https://doi.org/10.1002/ardp.202400714
• Fischer, T., & Riedl, R. (2022). Paracelsus’ legacy in the faunal realm : drugs deriving from animal toxins. Drug Discovery Today, 27(2), 567–575. https://doi.org/10.1016/j.drudis.2021.10.003
• Zizzari, A. T., Pliatsika, D., Gall, F., Fischer, T., & Riedl, R. (2021). New perspectives in oral peptide delivery. Drug Discovery Today, 26(4), 1097–1105. https://doi.org/10.1016/j.drudis.2021.01.020
• Fischer, T., & Riedl, R. (2020). Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Expert Opinion on Drug Discovery, 16(1), 75–88. https://doi.org/10.1080/17460441.2020.1819235
• Fischer, T., Koulas, S. M., Tsagkarakou, A. S., Kyriakis, E., Stravodimos, G. A., Skamnaki, V. T., Liggri, P. G. V., Zographos, S. E., Riedl, R., & Leonidas, D. D. (2019). High consistency of structure-based design and x-ray crystallography : design, synthesis, kinetic evaluation and crystallographic binding mode determination of biphenyl-N-acyl-β-D-glucopyranosylamines as glycogen phosphorylase inhibitors. Molecules, 24(7), 1322. https://doi.org/10.3390/molecules24071322
• Fischer, T., & Riedl, R. (2019). Inhibitory antibodies designed for matrix metalloproteinase modulation. Molecules, 24(12), 2265. https://doi.org/10.3390/molecules24122265
• Fischer, T., Gazzola, S., & Riedl, R. (2019). Approaching target selectivity by de novo drug design. Expert Opinion on Drug Discovery, 14(8), 791–803. https://doi.org/10.1080/17460441.2019.1615435
• Fischer, T., Senn, N., & Riedl, R. (2019). Design and structural evolution of matrix metalloproteinase inhibitors. Chemistry – A European Journal, 25(34), 7960–7980. https://doi.org/10.1002/chem.201805361
• Fischer, T., & Riedl, R. (2017). Cover picture : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor (ChemistryOpen 2/2017). ChemistryOpen, 6(2), 165. https://doi.org/10.1002/open.201700043
• Fischer, T., & Riedl, R. (2017). Targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor. ChemistryOpen, 6(2), 192–195. https://doi.org/10.1002/open.201600158
• Fischer, T., & Riedl, R. (2017). Cover profile : targeted fluoro positioning for the discovery of a potent and highly selective matrix metalloproteinase inhibitor. ChemistryOpen, 6(2), 167. https://doi.org/10.1002/open.201700042
• Fischer, T., & Riedl, R. (2017). Development of a non-hydroxamate dual matrix metalloproteinase (MMP)-7/-13 inhibitor. Molecules, 22(9). https://doi.org/10.3390/molecules22091548
• Fischer, T., & Riedl, R. (2016). Molecular recognition of the catalytic zinc(II) ion in MMP-13 : structure-based evolution of an allosteric inhibitor to dual binding mode inhibitors with improved lipophilic ligand efficiencies. International Journal of Molecular Sciences, 17(3/314). https://doi.org/10.3390/ijms17030314
• Fischer, T., & Riedl, R. (2013). Strategic targeting of multiple water-mediated interactions : a concise and rational structure-based design approach to potent and selective MMP-13 inhibitors. ChemMedChem, 8(9), 1457–1461. https://doi.org/10.1002/cmdc.201300278

Other publications

• Fischer, T., & Riedl, R. (2012). Design, synthesis and biological testing of novel MMP-inhibitors. Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 13 September 2012.
• Riedl, R., & Fischer, T. (2012). Structure based design and synthesis of novel MMP inhibitors. 19th EuroQSAR: «Knowledge Enabled Ligand Design», Vienna, Austria, 26-30 August 2012.
• Riedl, R., Fischer, T., Züger, P., & Brand, M. (2011, September). Structure based design and synthesis of novel MMP inhibitors. Fall Meeting 2011 of the Swiss Chemical Society, Lausanne, 9 September 2011.
• Riedl, R., & Fischer, T. (2010, September 16). Fragment based scaffold hopping in drug discovery. Fall Meeting 2012 of the Swiss Chemical Society, Zurich, 16 September 2010.

go back